Pfizer

Grants will be awarded in support of pre-clinical and translational research in multiple myeloma. Pre-clinical projects must have a focus on these areas of interest to be considered: correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy; understanding the kinetics of sBCMA vs long-term responses in the context of bispecific treatment; mechanisms of resistance; correlation between soluble BCMA and BCMA expression on myeloma cells; impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA; mechanistic understanding of the impact of anti-myeloma agents on elranatamab-mediated T-cell activation and anti-myeloma activity; exploring in-vitro or in-vivo novel combinations with elranatamab with a focus on drugs that are not currently SOC in myeloma; immunosuppressive mechanisms in the bone marrow that negatively impact bispecific activity; and comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab. Studies can be in-vitro or in-vivo or use existing patient samples (e.g., blood, bone marrow aspirates).

Eligible applicants must have a MD, PhD, or equivalent, a BSN with a MS/PhD, or a degree in pharmacy.